Literature DB >> 29458551

Short- and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena®) on vaginal microbiota and Candida.

Gilbert Gerard Ghislain Donders1,2,3, G Bellen2, Kateryna Ruban2, Ben Van Bulck4.   

Abstract

BACKGROUND: Recurrent vulvovaginal infections are a frequent complaint in young women in need of contraception. However, the influence of the contraceptive method on the course of the disease is not well known. AIM: To investigate the influence of the levonorgestrel-releasing intrauterine-system (LNG-IUS) on the vaginal microflora.
METHODS: Short-term (3 months) and long-term (1 to 5 years) changes of vaginal microbiota were compared with pre-insertion values in 252 women presenting for LNG-IUS insertion. Detailed microscopy on vaginal fluid was used to define lactobacillary grades (LBGs), bacterial vaginosis (BV), aerobic vaginitis (AV) and the presence of Candida. Cultures for enteric aerobic bacteria and Candida were used to back up the microscopy findings. Fisher's test was used to compare vaginal microbiome changes pre- and post-insertion.
RESULTS: Compared to the pre-insertion period, we found a temporary worsening in LBGs and increased rates of BV and AV after 3 months of LNG-IUS. After 1 and 5 years, however, these changes were reversed, with a complete restoration to pre-insertion levels. Candida increased significantly after long-term carriage of LNG-IUS compared to the period before insertion [OR 2.0 (CL951.1-3.5), P=0.017].
CONCLUSIONS: Short-term use of LNG-IUS temporarily decreases lactobacillary dominance, and increases LBG, AV and BV, but after 1 to 5 years these characteristics return to pre-insertion levels, reducing the risk of complications to baseline levels. Candida colonization, on the other hand, is twice as high after 1 to 5 years of LNG-IUS use, making it less indicated for long-term use in patients with or at risk for recurrent vulvovaginal candidosis.

Entities:  

Keywords:  abnormal vaginal flora; aerobic vaginitis; bacterial vaginosis; intrauterine device; recurrent Candida vaginitis

Mesh:

Substances:

Year:  2018        PMID: 29458551     DOI: 10.1099/jmm.0.000657

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  9 in total

1.  Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study.

Authors:  Kathryn Peebles; Flavia M Kiweewa; Thesla Palanee-Phillips; Catherine Chappell; Devika Singh; Katherine E Bunge; Logashvari Naidoo; Bonus Makanani; Nitesha Jeenarain; Doerieyah Reynolds; Sharon L Hillier; Elizabeth R Brown; Jared M Baeten; Jennifer E Balkus
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

2.  Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).

Authors:  Alex Farr; Isaak Effendy; Brigitte Frey Tirri; Herbert Hof; Peter Mayser; Ljubomir Petricevic; Markus Ruhnke; Martin Schaller; Axel P A Schäfer; Birgit Willinger; Werner Mendling
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

Review 3.  The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Authors:  Christophe d'Enfert; Ann-Kristin Kaune; Leovigildo-Rey Alaban; Sayoni Chakraborty; Nathaniel Cole; Margot Delavy; Daria Kosmala; Benoît Marsaux; Ricardo Fróis-Martins; Moran Morelli; Diletta Rosati; Marisa Valentine; Zixuan Xie; Yoan Emritloll; Peter A Warn; Frédéric Bequet; Marie-Elisabeth Bougnoux; Stephanie Bornes; Mark S Gresnigt; Bernhard Hube; Ilse D Jacobsen; Mélanie Legrand; Salomé Leibundgut-Landmann; Chaysavanh Manichanh; Carol A Munro; Mihai G Netea; Karla Queiroz; Karine Roget; Vincent Thomas; Claudia Thoral; Pieter Van den Abbeele; Alan W Walker; Alistair J P Brown
Journal:  FEMS Microbiol Rev       Date:  2021-05-05       Impact factor: 16.408

4.  Hormonal Contraception and Vaginal Infections Among Couples Who Are Human Immunodeficiency Virus Serodiscordant in Lusaka, Zambia.

Authors:  Lisa B Haddad; Kristin M Wall; Katherine Tote; William Kilembe; Bellington Vwailika; Tyronza Sharkey; Ilene Brill; Elwyn Chomba; Amanda Tichacek; Susan Allen
Journal:  Obstet Gynecol       Date:  2019-09       Impact factor: 7.623

5.  The healthy female microbiome across body sites: effect of hormonal contraceptives and the menstrual cycle.

Authors:  Maria Christine Krog; Luisa W Hugerth; Emma Fransson; Zahra Bashir; Anders Nyboe Andersen; Gabriella Edfeldt; Lars Engstrand; Ina Schuppe-Koistinen; Henriette Svarre Nielsen
Journal:  Hum Reprod       Date:  2022-06-30       Impact factor: 6.353

Review 6.  Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives.

Authors:  Jennifer Deese; Subarna Pradhan; Hannah Goetz; Charles Morrison
Journal:  Open Access J Contracept       Date:  2018-11-12

7.  The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions.

Authors:  Anita Mitra; David A MacIntyre; George Ntritsos; Ann Smith; Konstantinos K Tsilidis; Julian R Marchesi; Phillip R Bennett; Anna-Barbara Moscicki; Maria Kyrgiou
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

Review 8.  Immunological Role of the Maternal Uterine Microbiome in Pregnancy: Pregnancies Pathologies and Alterated Microbiota.

Authors:  Jonah Bardos; Desiree Fiorentino; Ryan E Longman; Michael Paidas
Journal:  Front Immunol       Date:  2020-01-08       Impact factor: 7.561

Review 9.  Vulvovaginal Candidosis: Current Concepts, Challenges and Perspectives.

Authors:  Valentina Sustr; Philipp Foessleitner; Herbert Kiss; Alex Farr
Journal:  J Fungi (Basel)       Date:  2020-11-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.